Description Proton pump inhibitors (PPIs) are among the most commonly used medications
in the world. Developed for the treatment and prevention of acid-mediated upper …

Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

Gastrinomas are neuroendocrine neoplasms, usually located in the duodenum or pancreas,
that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison syndrome …

The better understanding of the biological behavior of multiple endocrine neoplasia type 1
(MEN1) organ manifestations and the increase in clinical experience warrant a revision of …

Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …

Proton pump inhibitors have an excellent safety profile and have become one of the most
commonly prescribed class of drugs in primary and specialty care. Long-term, sometimes …

Background Proton pump inhibitors (PPI s) are a mainstay therapy for all gastric acid‐related
diseases. Clinical concerns arise from a small but growing number of case reports …

Although case reports link proton-pump inhibitor (PPI) use and hypomagnesemia, no large-
scale studies have been conducted. Here we examined the serum magnesium …

Background Proton pump inhibitors (PPI) are the most effective drugs for inhibiting gastric
acid secretion. They have been in clinical use for more than 25 years, In 2014, 3.475 billion …